Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

12 de agosto de 2026 actualizado por: Arjun Deb, MD

A Phase 1 Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AD-NP1, a Humanized Monoclonal Antibody Targeting Human ENPP1

This is a Phase 1 single-blind, placebo-controlled, dose-escalation study designed to evaluate the safety of AD-NP1, a humanized monoclonal antibody targeting human ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1). The study aims to assess the maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AD-NP1 in healthy volunteers. Participants will be randomized to receive either AD-NP1 or placebo, with safety and efficacy monitored in accordance with Good Clinical Practice (GCP) guidelines. The study also seeks to explore changes in health-related quality of life (HRQOL) during the trial.

Descripción general del estudio

Estado

Activo, no reclutando

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

36

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • California
      • Los Angeles, California, Estados Unidos, 90095
        • UCLA Clinical and Translational Research Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Body weight ≤ 90kg
  • Ability to understand and the willingness to sign a written informed consent document
  • Study subject must have read, understood, and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained
  • Be in general good health without history of any of the conditions listed in exclusion criteria
  • No use of any tobacco products for at least 6 months
  • Woman/women of childbearing potential (WOCBP) must agree not to become pregnant from the time of study enrollment until at least 6 months after the completion of the monoclonal antibody infusion. If a WOCBP is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel
  • Sexually active male subjects must use a barrier method of contraception during the study
  • Screening laboratory values must meet the following criteria:

    • WBC (>3,000 - <11,000/mm^3)
    • Platelets (>100,000/mm^3)
    • Hemoglobin (>10.5 gm/dl)
    • Creatinine (<1.1 x upper limit of normal [ULN])
    • BUN (<1.25 x ULN)
    • AST (<1.1 x ULN)
    • ALT (<1.1 x ULN)
    • Alkaline Phosphatase (<1.1 x ULN)
    • Bilirubin (<1.1 x ULN)
    • Glucose-non-fasting (> 60 mg/dl and < 115 mg/dl)
  • Human immunodeficiency virus (HIV)-infected individuals on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For subjects with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load

Exclusion Criteria:

  • Previous exposure to humanized or human monoclonal antibodies whether FDA approved or investigational
  • Weight > 90 kg
  • History of any of the following illnesses or conditions:
  • a. Respiratory condition (such as asthma requiring daily medication)
  • b. Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
  • c. Blood dyscrasias
  • d. Psychiatric disorder that precludes compliance with the clinical protocol
  • e. Hepatitis
  • Any chronic condition requiring daily prescription or over-the-counter medicine except for vitamins and birth control products
  • History of drug or alcohol abuse within previous 12 months or a positive urine toxicology screen within 24 hours of initial screening
  • History of a previous severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis
  • Physical finding on examination considered clinically significant such as heart murmur (other than functional), hepatosplenomegaly, lymphadenopathy, or focal neurological deficit
  • Urinalysis positive for > trace protein, >5 RBC/HPF or >5 WBC/HPF
  • Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen
  • Positive serum pregnancy test during screening or positive urine pregnancy test within 24 hours of monoclonal antibody administration, or an unwillingness to undergo pregnancy testing
  • Currently breast-feeding
  • Receipt of an FDA approved vaccine or any investigational study agent within previous 30 days
  • Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the subject participating in the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Cohort 1 - AD-NP1 (30mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 30 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Comparador de placebos: Cohort 1 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 30 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
Experimental: Cohort 2 - AD-NP1 (40 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 40 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Comparador de placebos: Cohort 2 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 40 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
Experimental: Cohort 3 - AD-NP1 (60 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 60 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Comparador de placebos: Cohort 3 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 60 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
Experimental: Cohort 4 - AD-NP1 (100 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 100 mg/kg
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1. It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
Comparador de placebos: Cohort 4 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 100 mg/kg dose of AD-NP1
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety and tolerability of escalating doses of a single IV dose of AD-NP1
Periodo de tiempo: Day of infusion (Day 0) to 28 days post-dose
Assessed by the incidence of treatment-related Adverse Events (AEs) using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Day of infusion (Day 0) to 28 days post-dose

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Maximum Tolerated Dose of AD-NP1
Periodo de tiempo: Day of infusion (Day 0) to 28 days post-dose
To be determined based on dose limiting toxicities (DLTs) and adverse events
Day of infusion (Day 0) to 28 days post-dose
Maximum Plasma Concentration (Cmax) as a pharmacokinetics (PK) parameter
Periodo de tiempo: Baseline (pre-dose) up to Day 60 post-dose
Peak plasma concentration obtained directly from the experimental data points, to be measured in Nanograms per milliliter (ng/mL)
Baseline (pre-dose) up to Day 60 post-dose
Time to Maximum Plasma Concentration (Tmax) as a pharmacokinetics (PK) parameter
Periodo de tiempo: Baseline (pre-dose) up to Day 60 post-dose
Tmax presents the time at which Cmax is observed, to be measured in hours (h) and minutes (m)
Baseline (pre-dose) up to Day 60 post-dose
Area Under the Plasma Concentration-Time Curve (AUC) as a pharmacokinetics (PK) parameter
Periodo de tiempo: Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
AUC calculated using the linear-log trapezoidal rule from time zero (pre-dose) to the last quantifiable concentration point to be measured in Nanogram x hours per milliliter (ng * h/mL)
Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
Terminal Elimination Half-life (T(1/2)) as a pharmacokinetics (PK) parameter
Periodo de tiempo: Baseline (pre-dose) up to Day 60 post-dose
The rate at which Ad-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
Baseline (pre-dose) up to Day 60 post-dose
Total Body Clearance (CL) as a pharmacokinetics (PK) parameter
Periodo de tiempo: Baseline (pre-dose) up to Day 60 post-dose
The rate at which AD-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
Baseline (pre-dose) up to Day 60 post-dose
Plasma Uridine Concentration
Periodo de tiempo: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of uridine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Cytidine Concentration
Periodo de tiempo: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of cytidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Orotidine Concentration
Periodo de tiempo: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of orotidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Adenine Concentration
Periodo de tiempo: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of adenine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma Carbamoyl Aspartate Concentration
Periodo de tiempo: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Plasma concentrations of carbamoyl aspartate will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
Immunogenicity of a single IV dose of AD-NP1
Periodo de tiempo: Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
Determined by measuring levels of circulating anti-drug antibody in blood samples
Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
Apparent Volume of Distribution (Vd) as a pharmacokinetics (PK) parameter
Periodo de tiempo: Baseline (pre-dose) up to Day 60 post-dose
Volume of distribution calculated during the terminal elimination phase following administration, to be measured in Liters (L) or Liters per kilogram (L/kg)
Baseline (pre-dose) up to Day 60 post-dose

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de junio de 2026

Finalización primaria (Estimado)

1 de enero de 2028

Finalización del estudio (Estimado)

1 de mayo de 2028

Fechas de registro del estudio

Enviado por primera vez

6 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

6 de agosto de 2026

Publicado por primera vez (Actual)

13 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

14 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 25-1584
  • PR250528 (Otro número de subvención/financiamiento: DOD-DEPARTMENT OF DEFENSE)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir